GlassScriptPhysician profile
Samir Alsawah
NPI 1063453413
$5,764.91
in general payments reported to CMS, 2019-2025
44 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $769 · 2021: $1,196 · 2022: $868 · 2023: $795 · 2024: $569 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.88 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $774.32 | 2019-2025 | |
| Janssen Biotech, INC. | $488.62 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals LP | $468.61 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Genzyme Corporation | $355.63 | 2021-2025 | |
| Pfizer INC. | $324.23 | 2019-2025 | |
| Exelixis INC. | $321.57 | 2019-2024 | Cabometyx |
| Amag Pharmaceuticals, INC. | $264.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $190.78 | 2021-2025 | Libtayo |
| Genentech USA, INC. | $179.54 | 2019-2024 | Tecentriq, Rozlytrek, Alecensa |
| Merck Sharp & Dohme LLC | $169.72 | 2019-2023 | Lynparza, Keytruda |
| Glaxosmithkline, LLC. | $155.40 | 2022-2025 | Ojjaara, Shingrix, Zejula |
| Amgen INC. | $151.87 | 2019-2022 | |
| Abbvie INC. | $140.08 | 2019-2024 | Venclexta |
| Seagen INC. | $138.34 | 2021-2022 | |
| Array Biopharma INC | $137.45 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Alsawah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.